DOCSLIB.ORG

Tennessee Coverrx Covered Drug List - Effective 10/1/2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tennessee Coverrx Covered Drug List - Effective 10/1/2021 Tennessee CoverRx Covered Drug List - Effective 10/1/2021 ANTIBIOTICS ARTHRITIS AND PAIN BEHAVIORAL HEALTH (CONT'D) DIABETES Amoxicillin Allopurinol Haloperidol Glimepiride Amoxicillin / Clavulanate Dexamethasone Haloperidol Decanoate Glipizide Ampicillin Diclofenac Sodium tablets Haloperidol Lactate 2 mg/ml Glipizide ER/XL Azithromycin Hydroxychloroquine Sulfate Hydroxyzine Pamoate Glyburide Cefaclor capsules Indomethacin Imipramine HCL Glyburide/Metformin Cefadroxil Ketoprofen Lithium Carbonate Humalog® cartridge* Cefpodoxime tablets Ketorolac* Loxapine Humalog® / Humalog® Mix pen* & KwikPen®* Cefuroxime tablets Meloxicam tablets Mirtazapine Humalog® / Humalog® Mix vial* Cephalexin capsules (except 750 mg) Methotrexate Nortriptyline Humulin® cartridge* Ciprofloxacin (except 750 mg & XR) Methylprednisolone Olanzapine IR tablets* Humulin® pen & KwikPen® (except U-500)* Clindamycin capsules Nabumetone Paroxetine tablets (not CR tablets) Humulin® vial (except U-500)* Dicloxacillin Prednisolone Sod-Phos solution Perphenazine Lantus® vials & Lantus® Solostar pens* Doxycycline Monohydrate capsule Prednisone tablets Quetiapine tablets (not ER tablets) Metformin tablets Erythromycin / Sulfisoxazole Salsalate Risperidone tablets Metformin ER (excluding osmotic ER & Levofloxacin tablets Sulindac Sertraline tablets modified release ER) Metronidazole (except lotion, *QUANTITY LIMITS: Thiothixene Pioglitazone 0.75% vaginal gel, & 1% gel) Ketorolac: 20 tablets per 60 days Trazodone Toujeo® Solostar / Max Solostar® Minocycline capsules ASTHMA AND RESPIRATORY Trifluoperazine Alcohol Swabs Neomycin Sulfate Ipratropium-albuterol Trihexyphenidyl tablets Freestyle® Freedom Lite meter Nitrofurantoin Macrocrystals Montelukast 5mg chew, 10mg tablet Venlafaxine IR tablets FreeStyle® InsuLinx meter / strips* Paromomycin Sulfate ProAir® HFA Venlafaxine ER capsules* FreeStyle® Lite meter / strips* Penicillin V Potassium ProAir® RespiClick *QUANTITY LIMITS: Insulin Syringes* Sulfamethoxazole / Trimethoprim Terbutaline Sulfate tablets Aripiprazole tablets: 1 tablet per day Lancet Devices / Lancets Trimethoprim Theophylline, Anhydrous, ER Duloxetine capsules: 2 capsules per day Precision® Xtra meter / strips* Olanzapine IR 2.5mg, 5mg, *QUANTITY LIMITS: ANTICONVULSANTS BEHAVIORAL HEALTH 7.5mg & 10mg tablets: 2 tablets per day Insulin: Lesser of 30-Day supply or 40ml per fill per type Divalproex DR tablets Amitriptyline Olanzapine IR 15mg & 20mg tablets: 1 tablet per day Insulin Test Strips: 100 per 30 days or 300 per 90 days Lamotrigine IR tablets Aripiprazole tablets (not ODT)* Venlafaxine ER capsules: 1 capsule per day Insulin Syringes: 100 per 30 days or 300 per 90 days Levetiracetam IR tablets Benztropine Insulin Pen Needles: 100 per 30 days or 300 per 90 days Oxcarbazepine IR tablets Bupropion SR BLOOD MODIFIERS Alcohol Swabs: 100 per 30 days or 300 per 90 days Phenytoin 100 mg capsules Bupropion XL 150 & 300 mg Clopidogrel 75 mg tablets Lancets: 100 per 30 days or 300 per 90 days Phenytoin suspension Buspirone Dipyridamole Valproic Acid Citalopram tablets Warfarin Sodium Clozapine (except 200 mg tablets) ANTIVIRALS Doxepin CHOLESTEROL Acyclovir (except topicals) Duloxetine capsules* Atorvastatin Amantadine Escitalopram tablets Fenofibrate 54 mg and 160 mg tablets Oseltamivir 75 mg capsules* Fluoxetine capsules (except DR) Gemfibrozil Rimantadine Fluphenazine Lovastatin *QUANTITY LIMITS: Fluphenazine Decanoate Pravastatin Oseltamivir: 20 capsules per 180 days Simvastatin Page 1 of 2 Tennessee CoverRx Covered Drug List - Effective 10/1/2021 EYE CARE AND GLAUCOMA HEART HEALTH & BLOOD PRESSURE (CONT'D) STOMACH HEALTH OTHER MEDICAL CONDITIONS Acetazolamide Carvedilol Dicyclomine capsules & tablets Allergies Atropine Sulfate Chlorthalidone Hyoscyamine drops Hydroxyzine HCL Brimonidine Tartrate 0.2% Clonidine tablet (not ER tablet) Hyoscyamine IR tablets Bone Density Cyclopentolate HCl 1% Digoxin Mesalamine Suppositories Alendronate Dexamethasone Sod-Phos Diltiazem, ER / XR Metoclopramide Ear Health Dorzolamide / Timolol Eye Drops Disopyramide Phosphate Sulfasalazine Neomycin/Polymyxin/HC Ear Drops Erythromycin Eye Ointment Enalapril / HCTZ Ursodiol tablets Migraines Gentamicin Sulfate 0.3% Felodipine ER Sumatriptan tablets* Homatropine HBr 5% Furosemide tablets THYROID CONDITIONS Skin Cream Latanoprost Hydralazine Levothyroxine, Levo-T, Euthyrox Triamcinolone Acetonide Cream Levobunolol HCl Hydrochlorothiazide Methimazole Miscellaneous Ofloxacin Eye Drops Indapamide Lactulose Pilocarpine Eye Drops Isosorbide Mononitrate UROLOGY Megestrol Acetate Polymyxin B / Trimethoprim Lisinopril Bethanechol Chloride Naloxone carpuject* Prednisolone Acetate Lisinopril / HCTZ Flavoxate Narcan® Nasal Spray* Sulfacetamide Sodium Losartan Oxybutynin HCl NRT-Nicotine Transdermal Patches*: 7mg,14mg, 21mg Timolol Maleate Losartan/HCTZ Phenazopyridine HCl Promethazine tablets Tobramycin Sulfate Metolazone *QUANTITY LIMITS: Metoprolol, ER VITAMINS AND MINERALS Naloxone carpuject: 2 inj. per month (not available FUNGAL INFECTIONS Mexiletine Calcitriol (except ointment) by mail order) Clotrimazole Nifedipine ER Ergocalciferol (Vitamin D2) capsules* Narcan® Nasal: 1 kit per month (not available Clotrimazole Troche Nitroglycerin (except patch) Folic acid 1 mg tablets by mail order) Fluconazole NitroStat Potassium Chloride Sumatriptan tablets: 9 tablets per month Ketoconazole (except foam) Prazosin 1 mg & 2 mg capsules* Prenatal Vitamins – All generics NRT Patches: 8 weeks per each strength annually Nystatin (except powder) Propafenone tablets *QUANTITY LIMITS: VACCINES Propranolol IR Ergocalciferol: 13 capsules per 90 days Afluria® HEART HEALTH & BLOOD PRESSURE Quinidine Gluconate Fluarix® Amiodarone (except 100 mg) Sotalol WOMEN’S HEALTH Flublok® Amlodipine Spironolactone Estradiol oral tablets, cream Flucelvax® Quad Amlodipine / Benazepril Terazosin Estropipate Flulaval® Atenolol Triamterene / HCTZ Medroxyprogesterone (not injection) Fluvirin® Atenolol / Chlorthalidone Verapamil tablets, ER / PM / SR Oral Contraceptives – All generics & Fluzone® Bisoprolol / HCTZ *QUANTITY LIMITS: Emergency Contraceptives Influenza A (H1N1) Bisoprolol Fumarate Prazosin: 1 capsule per day Tamoxifen Pneumovax® Benazepril Prevnar 13® COVID-19 Page 2 of 2.
Load more

Recommended publications
  • 2020 Prior Authorization Criteria
    2020 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS abiraterone tablet ...................................................................................................................... 217 ABRAXANE .............................................................................................................................. 131 ACTIMMUNE .............................................................................................................................. 14 ADASUVE ................................................................................................................................... 27 ADEMPAS ................................................................................................................................ 197 AFINITOR ................................................................................................................................. 217 AFINITOR DISPERZ ................................................................................................................. 217 AIMOVIG ..................................................................................................................................... 15 ALECENSA ............................................................................................................................... 217 ALIMTA ..................................................................................................................................... 131 ALIQOPA .................................................................................................................................
    [Show full text]
  • HALDOL Brand of Haloperidol Injection (For Immediate Release) WARNING Increased Mortality in Elderly Patients with Dementia
    HALDOL® brand of haloperidol injection (For Immediate Release) WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. HALDOL Injection is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS). DESCRIPTION Haloperidol is the first of the butyrophenone series of major antipsychotics. The chemical designation is 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]­ 4’-fluorobutyrophenone and it has the following structural formula: HALDOL (haloperidol) is available as a sterile parenteral form for intramuscular injection. The injection provides 5 mg haloperidol (as the lactate) and lactic acid for pH adjustment between 3.0 – 3.6.
    [Show full text]
  • Drug-Induced Angle-Closure Glaucoma
    10.5005/jp-journals-10008-1100 ArujREVIEW K Khurana ARTICLE et al Drug-induced Angle-Closure Glaucoma Aruj K Khurana, Bhawna Khurana, Ashok K Khurana Regional Institute of Ophthalmology, Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India Correspondence: Ashok K Khurana, Senior Professor, Regional Institute of Ophthalmology, Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India ABSTRACT Drug-induced angle-closure glaucoma is an important entity for the ophthalmologist as well as the general physician as it represents a preventable cause of potential blindness. This brief review highlights the fact that a high index of suspicion, in a susceptible individual followed by confirmation on appropriate imaging modality (UBM, ultrasound or anterior segment OCT) can alleviate the threat to sight and also help to institute appropriate therapy. Keywords: Acute angle closure, Drug-induced glaucoma. INTRODUCTION factors exist for this syndrome.9 Other sulfa-based drugs known Drug-induced angle-closure glaucoma is an important entity to be associated with AACG: Acetazolamide, hydrochloro- 10 for the ophthalmologist as well as the general physician as it thiazide and cotrimoxazole. represents a preventable cause of potential blindness.1 Acute Anticholinergic drugs implicated in the causation of AACG angle-closure glaucoma can develop in a susceptible individual include atropine, homatropine, cyclopentolate and ipratropium by various classes of drugs.2 Practitioners using any of these bromide.10,11 Atropine is often used to treat bradycardia, drugs should be aware of their potential to cause acute angle especially related to general anesthesia. Postoperative AACG closure, such that a patient presenting with signs or symptoms has been reported in patients after general anesthesia for of acute angle closure should be immediately referred to an abdominal, orthopedic, facial and endoscopic surgery.12 3 ophthalmologist.
    [Show full text]
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on 2 Nav1.5 Channels
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.059188; this version posted August 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Inhibitory effect of eslicarbazepine acetate and S-licarbazepine on 2 Nav1.5 channels 3 Theresa K. Leslie1, Lotte Brückner 1, Sangeeta Chawla1,2, William J. Brackenbury1,2* 4 1Department of Biology, University of York, Heslington, York, YO10 5DD, UK 5 2York Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, UK 6 * Correspondence: Dr William J. Brackenbury, Department of Biology and York Biomedical 7 Research Institute, University of York, Wentworth Way, Heslington, York YO10 5DD, UK. Email: 8 [email protected]. Tel: +44 1904 328284. 9 Keywords: Anticonvulsant, cancer, epilepsy, eslicarbazepine acetate, Nav1.5, S-licarbazepine, 10 voltage-gated Na+ channel. 11 Abstract 12 Eslicarbazepine acetate (ESL) is a dibenzazepine anticonvulsant approved as adjunctive treatment for 13 partial-onset epileptic seizures. Following first pass hydrolysis of ESL, S-licarbazepine (S-Lic) 14 represents around 95 % of circulating active metabolites. S-Lic is the main enantiomer responsible 15 for anticonvulsant activity and this is proposed to be through the blockade of voltage-gated Na+ 16 channels (VGSCs). ESL and S-Lic both have a voltage-dependent inhibitory effect on the Na+ current 17 in N1E-115 neuroblastoma cells expressing neuronal VGSC subtypes including Nav1.1, Nav1.2, 18 Nav1.3, Nav1.6 and Nav1.7.
    [Show full text]
  • Anti-Inflammatory Effects of Amantadine and Memantine
    Journal of Personalized Medicine Communication Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? Félix Javier Jiménez-Jiménez 1,* , Hortensia Alonso-Navarro 1 , Elena García-Martín 2 and José A. G. Agúndez 2 1 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, E-28500 Madrid, Spain; [email protected] 2 University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, E-10071 Cáceres, Spain; [email protected] (E.G.-M.); [email protected] (J.A.G.A.) * Correspondence: [email protected]; Tel.: +34-636968395 Received: 2 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Abstract: We have reviewed current data on the anti-inflammatory effects of amantadine and memantine in clinical and in vivo models of inflammation, and we propose that these effects have potential interest for the treatment of the SARS-CoV-2 infection (COVID-19 disease). To that end, we performed a literature search using the PubMed Database from 1966 up to October 31 2020, crossing the terms “amantadine” and “memantine” with “inflammation” and “anti-inflammatory”. Amantadine and/or memantine have shown anti-inflammatory effects in chronic hepatitis C, in neuroinflammation induced by sepsis and by lipopolysaccharides, experimental models of multiple sclerosis, spinal cord injury, and respiratory diseases. Since the inflammatory response is one of the main pathogenetic mechanisms in the progression of the SARS-CoV-2 infection, anti-inflammatory effects of amantadine and memantine could be hypothetically useful in the treatment of this condition. This potential utility deserves further research. Keywords: amantadine; memantine; anti-inflammatory effects; SARS-Cov-2; COVID-19; therapy 1.
    [Show full text]
  • Non-Steroidal Drug-Induced Glaucoma MR Razeghinejad Et Al 972
    Eye (2011) 25, 971–980 & 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11 www.nature.com/eye 1,2 1 1 Non-steroidal drug- MR Razeghinejad , MJ Pro and LJ Katz REVIEW induced glaucoma Abstract vision. The majority of drugs listed as contraindicated in glaucoma are concerned with Numerous systemically used drugs are CAG. These medications may incite an attack in involved in drug-induced glaucoma. Most those individuals with narrow iridocorneal reported cases of non-steroidal drug-induced angle.3 At least one-third of acute closed-angle glaucoma are closed-angle glaucoma (CAG). glaucoma (ACAG) cases are related to an Indeed, many routinely used drugs that have over-the-counter or prescription drug.1 Prevalence sympathomimetic or parasympatholytic of narrow angles in whites from the Framingham properties can cause pupillary block CAG in study was 3.8%. Narrow angles are more individuals with narrow iridocorneal angle. The resulting acute glaucoma occurs much common in the Asian population. A study of a more commonly unilaterally and only rarely Vietnamese population estimated a prevalence 4 bilaterally. CAG secondary to sulfa drugs is a of occludable angles at 8.5%. The reported bilateral non-pupillary block type and is due prevalence of elevated IOP months to years to forward movement of iris–lens diaphragm, after controlling ACAG with laser iridotomy 5,6 which occurs in individuals with narrow or ranges from 24 to 72%. Additionally, a open iridocorneal angle. A few agents, significant decrease in retinal nerve fiber layer including antineoplastics, may induce thickness and an increase in the cup/disc ratio open-angle glaucoma.
    [Show full text]
  • Eslicarbazepine Acetate: a New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
    Drugs R D DOI 10.1007/s40268-017-0197-5 REVIEW ARTICLE Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures 1 1 1 Graciana L. Galiana • Angela C. Gauthier • Richard H. Mattson Ó The Author(s) 2017. This article is an open access publication Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family Key Points that is currently approved as adjunctive therapy and monotherapy for partial-onset (focal) seizures. The drug Eslicarbazepine acetate is an effective and safe enhances slow inactivation of voltage-gated sodium chan- treatment option for partial-onset seizures as nels and subsequently reduces the activity of rapidly firing adjunctive therapy and monotherapy. neurons. Eslicarbazepine acetate has few, but some, drug– drug interactions. It is a weak enzyme inducer and it Eslicarbazepine acetate improves upon its inhibits cytochrome P450 2C19, but it affects a smaller predecessors, carbamazepine and oxcarbazepine, by assortment of enzymes than carbamazepine. Clinical being available in a once-daily regimen, interacting studies using eslicarbazepine acetate as adjunctive treat- with a smaller range of drugs, and causing less side ment or monotherapy have demonstrated its efficacy in effects. patients with refractory or newly diagnosed focal seizures. The drug is generally well tolerated, and the most common side effects include dizziness, headache, and diplopia. One of the greatest strengths of eslicarbazepine acetate is its ability to be administered only once per day. Eslicar- 1 Introduction bazepine acetate has many advantages over older anti- epileptic drugs, and it should be strongly considered when Epilepsy is a common neurological disorder affecting over treating patients with partial-onset epilepsy.
    [Show full text]
  • Medication Conversion Chart
    Fluphenazine FREQUENCY CONVERSION RATIO ROUTE USUAL DOSE (Range) (Range) OTHER INFORMATION KINETICS Prolixin® PO to IM Oral PO 2.5-20 mg/dy QD - QID NA ↑ dose by 2.5mg/dy Q week. After symptoms controlled, slowly ↓ dose to 1-5mg/dy (dosed QD) Onset: ≤ 1hr 1mg (2-60 mg/dy) Caution for doses > 20mg/dy (↑ risk EPS) Cmax: 0.5hr 2.5mg Elderly: Initial dose = 1 - 2.5mg/dy t½: 14.7-15.3hr 5mg Oral Soln: Dilute in 2oz water, tomato or fruit juice, milk, or uncaffeinated carbonated drinks Duration of Action: 6-8hr 10mg Avoid caffeinated drinks (coffee, cola), tannics (tea), or pectinates (apple juice) 2° possible incompatibilityElimination: Hepatic to inactive metabolites 5mg/ml soln Hemodialysis: Not dialyzable HCl IM 2.5-10 mg/dy Q6-8 hr 1/3-1/2 po dose = IM dose Initial dose (usual): 1.25mg Onset: ≤ 1hr Immediate Caution for doses > 10mg/dy Cmax: 1.5-2hr Release t½: 14.7-15.3hr 2.5mg/ml Duration Action: 6-8hr Elimination: Hepatic to inactive metabolites Hemodialysis: Not dialyzable Decanoate IM 12.5-50mg Q2-3 wks 10mg po = 12.5mg IM CONVERTING FROM PO TO LONG-ACTING DECANOATE: Onset: 24-72hr (4-72hr) Long-Acting SC (12.5-100mg) (1-4 wks) Round to nearest 12.5mg Method 1: 1.25 X po daily dose = equiv decanoate dose; admin Q2-3wks. Cont ½ po daily dose X 1st few mths Cmax: 48-96hr 25mg/ml Method 2: ↑ decanoate dose over 4wks & ↓ po dose over 4-8wks as follows (accelerate taper for sx of EPS): t½: 6.8-9.6dy (single dose) ORAL DECANOATE (Administer Q 2 weeks) 15dy (14-100dy chronic administration) ORAL DOSE (mg/dy) ↓ DOSE OVER (wks) INITIAL DOSE (mg) TARGET DOSE (mg) DOSE OVER (wks) Steady State: 2mth (1.5-3mth) 5 4 6.25 6.25 0 Duration Action: 2wk (1-6wk) Elimination: Hepatic to inactive metabolites 10 4 6.25 12.5 4 Hemodialysis: Not dialyzable 20 8 6.25 12.5 4 30 8 6.25 25 4 40 8 6.25 25 4 Method 3: Admin equivalent decanoate dose Q2-3wks.
    [Show full text]
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2001; 4 (1), 53-56 Different beta-blocking effects of carvedilol and bisoprolol in humans Koshucharova G, Klein W, Lercher P, Maier R, Stepan V Stoschitzky K, Zweiker R Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL CARDIOLOGY Different Beta-Blocking Effects of Carvedilol and Bisoprolol J Clin Basic Cardiol 2001; 4: 53 Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans G. Koshucharova, R. Zweiker, R. Maier, P. Lercher, V. Stepan, W. Klein, K. Stoschitzky Bisoprolol is a beta1-selective beta-adrenergic antagonist while carvedilol is a non-selective beta-blocker with additional blockade of alpha1-adrenoceptors. Administration of bisoprolol has been shown to cause up-regulation of β-adrenoceptor density and to decrease nocturnal melatonin release, whereas carvedilol lacks these typical effects of beta-blocking drugs. The objective of the present study was to investigate beta-blocking effects of bisoprolol and carvedilol in healthy subjects. We compared the effects of single oral doses of clinically recommended amounts of bisoprolol (2.5, 5 and 10 mg) and carvedilol (25, 50 and 100 mg) to those of placebo in a randomised, double-blind, cross-over study in 12 healthy male volun- teers. Three hours after oral administration of the drugs heart rate and blood pressure were measured at rest, after 10 min. of exercise, and after 15 min.
    [Show full text]